These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 38040417)

  • 1. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
    Hua X; Xu Q; Wu R; Sun W; Gu Y; Zhu S; Liu X; Lv T; Song Y
    J Exp Clin Cancer Res; 2024 Jun; 43(1):164. PubMed ID: 38872221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.
    Liao H; Chang X; Gao L; Ye C; Qiao Y; Xie L; Lin J; Cai S; Dong H
    J Transl Med; 2023 Nov; 21(1):828. PubMed ID: 37978543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-18 serves as a main effector of CAF-derived METTL3 against immunosuppression of NSCLC via driving NF-κB pathway.
    Xu L; Li K; Li J; Xu F; Liang S; Kong Y; Chen B
    Epigenetics; 2023 Dec; 18(1):2265625. PubMed ID: 37871286
    [No Abstract]   [Full Text] [Related]  

  • 10. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.
    Luo YH; Yang YP; Chien CS; Yarmishyn AA; Adekunle Ishola A; Chien Y; Chen YM; Tsai PH; Lin TW; Wang ML; Chiou SH
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
    Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.